Jan 8 (Reuters) - Revance Therapeutics Inc:
* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS
* REVANCE THERAPEUTICS INC - TRIAL‘S PRIMARY ENDPOINT SHOWED ROBUST IMPACT ON PAIN, WITH GREATER THAN 50% REDUCTION FOR PATIENTS TREATED WITH RT002
* REVANCE THERAPEUTICS INC - RT002 APPEARED TO BE GENERALLY SAFE AND WELL-TOLERATED THROUGH WEEK 8
* REVANCE THERAPEUTICS - EXPECT TO CONDUCT ANOTHER PHASE 2A TRIAL WITH MODIFIED DESIGN TO DEMONSTRATE RT002‘S ABILITY TO TREAT PLANTAR FASCIITIS Source text for Eikon: Further company coverage:
 